首发未用药精神分裂症患者的糖耐量受损
Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia.
作者信息
Spelman L M, Walsh P I, Sharifi N, Collins P, Thakore J H
机构信息
Neuroscience Centre, St Vincent's Hospital, Dublin, Ireland.
出版信息
Diabet Med. 2007 May;24(5):481-5. doi: 10.1111/j.1464-5491.2007.02092.x. Epub 2007 Mar 22.
AIMS
To determine whether there is an association between Type 2 diabetes mellitus and schizophrenia, independent of medication.
METHODS
In this cross-sectional study we performed an oral glucose tolerance test on 38 non-obese white Caucasians who fulfilled the criteria for first-episode drug-naïve schizophrenia, 38 control subjects (matched for age, gender, smoking status, alcohol intake and ethnicity) and 44 first-degree relatives of the patients.
RESULTS
The frequency of impaired glucose tolerance (IGT), defined by World Health Organization criteria, was 10.5% (n = 4) in patients with schizophrenia, 18.2% (n = 8) in unaffected relatives and 0.0% in healthy control subjects (chi(2) = 4.22, d.f. = 2, P < 0.05).
CONCLUSIONS
The high point prevalence of IGT in never-treated patients and relatives supports either shared environmental or genetic predisposition to IGT. Both patients and their relatives present an ideal cost-effective opportunity to screen for Type 2 diabetes mellitus, as they are both easily identifiable.
目的
确定2型糖尿病与精神分裂症之间是否存在独立于药物治疗的关联。
方法
在这项横断面研究中，我们对38名符合首次发作、未服用过药物的精神分裂症标准的非肥胖白人进行了口服葡萄糖耐量试验，38名对照受试者（在年龄、性别、吸烟状况、酒精摄入量和种族方面匹配）以及44名患者的一级亲属。
结果
根据世界卫生组织标准定义的糖耐量受损（IGT）频率在精神分裂症患者中为10.5%（n = 4），在未患病亲属中为18.2%（n = 8），在健康对照受试者中为0.0%（χ² = 4.22，自由度 = 2，P < 0.05）。
结论
未接受治疗的患者及其亲属中IGT的高现患率支持IGT存在共同的环境或遗传易感性。患者及其亲属都是筛查2型糖尿病的理想且具有成本效益的对象，因为他们都易于识别。
Zotero 插件